GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) announced that its management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, September 14, 2026, at 11:30 a.m. ET. A live and replay webcast will be available via the investor relations section of GRAIL's website for at least 30 days.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 07 | FDA review scheduling | Positive | +9.6% | FDA advisory committee meeting scheduled to review Galleri PMA application |
| Aug 05 | Q2 earnings report | Neutral | -14.5% | Q2 revenue growth accompanied by net loss and negative adjusted EBITDA |
| Jul 30 | Conference presentation | Neutral | -3.6% | Management presentation at Canaccord Genuity annual growth conference |
| Jul 29 | Earnings date notice | Neutral | +12.1% | Company scheduled Q2 results release and management webcast |
| Jul 16 | Partnership announcement | Positive | -3.2% | Priority Health collaboration expanded Galleri access to employer groups |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed: the comparable conference announcement was followed by -3.63%, while partnership and earnings reports also recorded declines despite constructive elements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live and replay webcast may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-morgan-stanleys-24th-annual-global-healthcare-conference-302865242.html
SOURCE GRAIL, Inc.